{
  "id": "58f0b0c070f9fc6f0f000006",
  "type": "factoid",
  "question": "What is the indication for valbenazine?",
  "ideal_answer": "Valbenazine granted breakthrough drug status for treating tardive dyskinesia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25809133",
    "http://www.ncbi.nlm.nih.gov/pubmed/27819145"
  ],
  "snippets": [
    {
      "text": "VMAT2 inhibitors (e.g. deutetrabenazine and valbenazine) have been studied in the treatment of HD-related chorea, tardive dyskinesia and tics associated with Tourette syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27819145",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Valbenazine granted breakthrough drug status for treating tardive dyskinesia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25809133",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The FDA lowered approval hurdles for valbenazine due to a successful Phase II trial, which showed a distinctive improvement in tardive dyskinesia symptoms during valbenazine administration. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25809133",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Valbenazine granted breakthrough drug status for treating tardive dyskinesia."
}